A Flawed Study Shows How Little We Understand Crispr's Effects
Apr 04, 2018•5 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Biotech has been betting big on Crispr, the gene-editing technique that promises to snip away some of humanity’s worst diseases. But last May, a small case study suggested the much-hyped technology might actually be quite dangerous—and pop went the Crispr bubble, briefly tanking shares of Crispr companies like Editas Medicine, Intellia Therapeutics, and Crispr Therapeutics.
Learn about your ad choices: dovetail.prx.org/ad-choices
For the best experience, listen in Metacast app for iOS or Android